# US 2004/0082017 A1 · Methods and compositions for targeting secretory lysosomes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082017 A1
- Document ID: US20040082017A1
- Status: Published application
- Kind: A1
- Application number: 10/637,887
- Filed: 2003-08-08
- Published: 2004-04-29
- Earliest claimed: 2002-08-14
- Assignees: Boehringer Ingelheim Phamaceuticals, Inc.
- Inventors: Daniel Rajotte; Alisa Kabcenell
- Web page: https://patentgrep.com/patent/US20040082017A1

## CPC

- G01N 33/5005: {involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025)}
- C07K 14/43595: {from coelenteratae, e.g. medusae}
- C07K 2319/055: containing a signal for localisation to secretory granules (for exocytosis)
- C07K 2319/60: containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

This invention relates to methods and compositions for targeting proteins to secretory lysosomes. The invention further provides methods of use in drug screening assays, and methods of purifying secretory lysosomes.

## Claims

### Claim 1

A secretory lysosome targeting fusion moiety comprising: (a) a polypeptide that specifically localizes to a secretory lysosome and (b) a label polypeptide.

### Claim 2

A secretory lysosome targeting fusion moiety comprising: (a) a nucleotide sequence encoding a polypeptide that specifically localizes to a secretory lysosome and (b) a nucleotide sequence encoding a label polypeptide.

### Claim 3 (depends on 1, 2)

The secretory lysosome targeting fusion moiety according to claim 1 or claim 2 wherein the polypeptide that specifically localizes to a secretory lysosome comprises a protease selected from the group consisting of: tryptases, chymases and carboxypeptidsases.

### Claim 4 (depends on 3)

The secretory lysosome targeting fusion moiety according to claim 3 wherein the protease is selected from the group consisting of: Mouse Mast Cell Protease (MMCP)-1, -2, -3. -4, -5, -6, and -7; Rat Mast Cell Protease (RMCP) I and RMCP II; human chymases; human tryptases; Cathepsin G-like protease; Cathepsin G; carboxypeptidase A; and hexosaminidase.

### Claim 5 (depends on 4)

The secretory lysosome targeting fusion moiety according to claim 4 wherein the protease is Rat Mast Cell Protease (RMCP) II according to GenBank accession no. J02712.

### Claim 6 (depends on 1, 2)

The secretory lysosome targeting fusion moiety according to claim 1 or claim 2 wherein the label polypeptide is a fluorescent molecule.

### Claim 7 (depends on 1, 2)

A cell comprising a secretory lysosome targeting fusion moiety according to claim 1 or claim 2.

### Claim 8 (depends on 7)

The cell according to claim 7 wherein the label polypeptide is a fluorescent molecule.

### Claim 9 (depends on 8)

The cell according to claim 8 wherein the fluorescent molecule is Discosoma sp. red fluorescent protein or green fluorescent protein.

### Claim 10 (depends on 7)

The cell according to claim 7, wherein the cell is selected from the group consisting of: mast cells, basophils, hemopoietic cells, melanocytes, and goblet cells.

### Claim 11 (depends on 10)

The cell according to claim 10, wherein the cell is a mast cell.

### Claim 12

A cell line expressing a secretory lysosome targeting fusion moiety as deposited with the American Type Culture Collection and assigned accession number PTA-4571.

### Claim 13

A method for detecting and quantifying degranulation comprising: (a) incubating a cell expressing a secretory lysosome targeting fusion moiety comprising a label molecule in the presence of a cell activator; (b) incubating the cell expressing the secretory lysosome targeting fusion moiety comprising a label molecule in the absence of the cell activator; and (c) detecting and quantifying the release of label in the supernatant in the presence of the cell activator compared to the release of label in the supernatant in the absence of the cell activator, wherein an increase in the release of label in the supernatant in the presence of the cell activator indicates degranulation.

### Claim 14

A method for detecting and quantifying inhibition of degranulation comprising: (a) incubating a cell expressing a secretory lysosome targeting fusion moiety comprising a label molecule with a cell activator in the presence of a test substance; (b) incubating the cell expressing the secretory lysosome targeting fusion moiety comprising a label molecule with the cell activator in the absence of the test substance; and (c) detecting and quantifying a change in the release of label in the supernatant in the presence of the test substance compared to the release of label in the supernatant in the absence of test substance, wherein a decrease in the release of label in the supernatant in the presence of test substance indicates inhibition of degranulation.

### Claim 15

A method for detecting and quantifying degranulation at the single cell level comprising: (a) incubating a cell expressing a secretory lysosome targeting fusion moiety comprising a label molecule in the absence of a cell activator; (b) detecting and quantifying the amount of label in the absence of a cell activator, (c) incubating the cell of step (a) in the presence of a cell activator; (d) detecting and quantifying the amount of label in the presence of the cell activator; and (e) detecting a change in the amount of label in the cell in the presence of the cell activator compared to the amount of label in the cell in the absence the cell activator, wherein a decrease in the amount of label indicates degranulation.

### Claim 16

A method for detecting and quantifying degranulation at the single cell level comprising: (a) incubating a cell expressing a secretory lysosome targeting fusion moiety comprising a label molecule in the presence of a cell activator; (b) detecting and quantifying the amount of label in the presence of the cell activator, (c) incubating the cell of step (a) in the presence of the cell activator and a test substance; (d) detecting and quantifying the amount of label in the presence of the cell activator and the test substance; and (e) comparing the amount of label in the cell in the presence of the test substance to the amount of label in the cell in the absence the test substance, wherein an increase in the amount of label in the presence of the test compound indicates degranulation.

### Claim 17 (depends on 13, 14, 15, 16)

The method according to any one of claims 13 to 16 wherein the cell expressing a secretory lysosome targeting fusion moiety is selected from the group consisting of: mast cells, basophils, hemopoietic cells, melanocytes, and goblet cells.

### Claim 18 (depends on 13, 14, 15, 16)

The method according to any one of claims 13 to 16 wherein the cell expressing a secretory lysosome targeting fusion moiety is a mast cell.

### Claim 19 (depends on 13, 14, 15, 16)

The method according to any one of claims 13 to 16 wherein the label molecule is a fluorescent molecule.

### Claim 20 (depends on 19)

The method according to claim 19 wherein the fluorescent molecule is Discosoma sp. red fluorescent protein or green fluorescent protein.

### Claim 21 (depends on 13, 14, 15, 16)

The method according to any one of claims 13 to 16 wherein the secretory lysosome targeting fusion moiety comprises a nucleotide acid sequence encoding a protease selected from the group consisting of: tryptases, chymases and carboxypeptidases.

### Claim 22 (depends on 13, 14, 15, 16)

The method according to any one of claims 13 to 16 wherein the protease is selected from the group consisting of: Mouse Mast Cell Protease (MMCP)-1, -2, -3. -4, -5, -6, and -7; Rat Mast Cell Protease (RMCP) I and RMCP II; human chymases; human tryptases; Cathepsin G-like protease; Cathepsin G; carboxypeptidase A; and hexosaminidase.

### Claim 23 (depends on 13, 14, 15, 16)

The method according to any one of claims 13 to 16 wherein the protease is Rat Mast Cell Protease (RMCP) II.

### Claim 24 (depends on 13, 14, 15, 16)

The method according to any one of claims 13 to 16 wherein the cell line expressing the secretory lysosome targeting fusion moiety is the cell line as deposited with the American Type Culture Collection and assigned accession number PTA-4571.

### Claim 25 (depends on 13, 14, 15, 16)

The method according to any one of claims 13 to 16 wherein the cell activator is selected from the group consisting of: IgE and a multivalent antigen, phorbol myristate acetate, ionomycin, compound 48/80, toll-like receptors, and protease receptors

### Claim 26 (depends on 13, 14, 15, 16)

The method according to any one of claims 13 to 16 wherein the cell activator is selected from the group consisting of: IgE and a multivalent antigen, phorbol myristate acetate, and ionomycin.
